Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Improved algorithms have resulted in a proposed redesign of detection system. Once completed, a new trial will be planned.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main goal of this project is to assess the ability of a recently developed Breast Microwave Imaging (BMI) system to detect abnormalities in a human breast. These trials will be performed by recruiting fourteen volunteers that have been diagnosed with breast abnormalities using x-ray mammography. The breast presenting the abnormality will be imaged using the BMI system in a controlled and comfortable environment. As this is a feasibility study of the technology, and has the main goal to evaluate the diagnostic accuracy of this technology. The data collected from this study will be used to: (1) evaluate the overall participant experience during the BMI imaging procedure, (2) optimize the design of the BMI imaging system (both hardware and software), (3) open discussions with other medical professionals (e.g. radiologists) about the clinical feasibility of this emerging diagnostic imaging modality.
The Breast Microwave Imaging (BMI) system that will be used in this study is designed to detect breast abnormalities using low power microwave waveforms. The system is formed by three main components:
The system takes between 7.5 to 10 minutes to collect a three dimensional dataset from a single breast.
The BMI system used in the study operates in the frequency range of 20 megahertz (MHz) to 9 gigahertz (GHz). Canadian safety limits for the interaction of these non-ionizing electromagnetic waves with humans are outlined in the Health Canada publication "Safety Code 6: Limits of Human Exposure to Radiofrequency Electromagnetic Energy in the Frequency Range from 3 kilohertz (kHz) to 300 GHz [1]. For unregulated environments, the Specific Absorption Rate (SAR) limit set by Health Canada is 1.6 W/Kg. In the system used in this study, radio-frequency energy is generated via the Vector Network Analyzer (VNA). If the VNA is set at its maximum output power, which is 3.2 milliwatt (mW), the power received at 5 cm from the antenna (which is the distance where the breast will be) was measured to be 890 microwatt, which would yield a SAR value of 0.0196 W/kg.
References
[1] Consumer and Clinical Radiation Protection Bureau, Limits of Human Exposure to Radiofrequency Electromagnetic Energy in the Frequency Range from 3 kHz to 300 GHz, Health Canada, Ottawa, Ontario, 2015.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Abnormal x-ray Mammography group | Experimental | A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Breast Microwave Imaging | Device | A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care). |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic Accuracy (NO units) | Diagnostic Accuracy = (TP+TN)/(TP+FP+FN+TN): The fraction of patients that are diagnosed accurately, which is in turn a function of the Sensitivity and Specificity of the test. Sensitivity: The probability that a test result will be positive when the disease is present (true-positive fraction) = TP/(TP+FN) Specificity: The probability that a test result will be normal when the disease is absent (true-negative fraction) = TN/(FP+TN) TP = True Positive TN = True Negative FP = False Positive FN = False Negative | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity (NO units) | Sensitivity: The probability that a test result will be positive when the disease is present (true-positive fraction) = TP/(TP+FN) TP = True Positive TN = True Negative FP = False Positive FN = False Negative | 1 year |
| Specificity (NO units) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephen Pistorius, Ph.D. | University of Manitoba | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001941 | Breast Diseases |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Specificity: The probability that a test result will be normal when the disease is absent (true-negative fraction) = TN/(FP+TN) TP = True Positive TN = True Negative FP = False Positive FN = False Negative |
| 1 year |